NetworkNewsBreaks Archive - Page 1859 of 1951

WednesdayMay 17, 2017 11:12 am

NetworkNewsBreaks – Consilium Global Research Report Projects ChineseInvestors.com, Inc. (CIIX) Will Reach $14.8M in Revenues by FY2020

A recent research report published by Consilium Global Research predicts that ChineseInvestors.com (OTCQB: CIIX) will reach revenues of $14.8 million by fiscal year 2020 and that the company will undergo a major transformation this year as it pursues a bigger stake in the cannabis market. As cited in the report, ChineseInvestors.com achieved $930,000 in revenue for FY 2016, and the company is projected to continue growing at an estimated CAGR of 100 percent through 2020, while the underlying market’s CAGR is predicted to grow at a rate of 80 percent. “Headquartered in San Gabriel, California, CIIX offers a range of…

WednesdayMay 17, 2017 11:10 am

NetworkNewsBreaks – Ocera Therapeutics, Inc. (NASDAQ: OCRX) Reiterated with “Buy” Rating at Aegis Capital

Aegis Capital has reiterated a ‘Buy’ rating and price target of $3 on Ocera Therapeutics (NASDAQ: OCRX) following the company’s recent report of financial results for the quarter ended March 31, 2017. Ocera reported cash, cash equivalents and marketable securities of $25.2 million and restated prior guidance of cash on hand supporting operations into the second quarter of 2018. The company also provided an update on its clinical development programs of OCR-002 for the treatment of hepatic encephalopathy (HE). The company is expected to have an end of phase 2 meeting with the FDA in the third quarter of 2017, which…

WednesdayMay 17, 2017 11:08 am

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on Akebia Therapeutics, Inc. (NASDAQ: AKBA)

Aegis Capital has reiterated a ‘Buy’ rating and a price target of $25 on Akebia Therapeutics (NASDAQ: AKBA) following the company’s recent report of financial results for the first quarter ended March 31, 2017. Akebia reported cash, cash equivalents and marketable securities of $251.8 million. Combined with additional upcoming payments, the company said it expects to have resources to fund the current operating plan into the first quarter of 2019. Among other highlights, the analyst noted Akebia’s upcoming milestones, including the top-line results of a phase 2 trial in Japan in the second half of 2017; the initiation of a…

WednesdayMay 17, 2017 10:09 am

NetworkNewsBreaks – SinglePoint, Inc. (SING) Enters Letter of Intent to Acquire Stake in Discount Indoor Garden Supply

Specialized holding company SinglePoint, Inc. (OTC: SING) this morning announced its entry into a Letter of Intent with Discount Indoor Garden Supply (“DIGS”). Per the terms of the LOI, SinglePoint will acquire 90 percent of DIGS in a stock and cash transaction. The company anticipates that the acquisition will bring immediate revenues to SinglePoint while positioning it as a leader in online products, retail stores, cannabis consulting and equipment in California. “We are committed to identifying and making investments that will strengthen both parties' position in the cannabis industry while building SinglePoint's corporate value,” Greg Lambrecht, CEO of SinglePoint, stated…

WednesdayMay 17, 2017 9:49 am

NetworkNewsBreaks – SRAX (NASDAQ: SRAX) Presenting at 18th Annual B. Riley Co. Investor Conference on May 24

Internet advertising company SRAX (NASDAQ: SRAX) this morning announced plans to present at the 18th Annual B. Riley Co. Investor Conference, an invitation-only conference offering premier networking and business development opportunities with an attractive beachfront setting. The company’s presentation is scheduled to take place on Wednesday, May 24, 2017, at 3:25 p.m. PT at the newly-renovated Loews Santa Monica Beach Hotel in Santa Monica, California. In addition to the company’s presentation, SRAX CEO Christopher Miglino and CFO J.P. Hannan will be hosting one-on-one meetings with investors throughout the day. Interested parties should contact Kirsten Chapman at SRAX@lhai.com or 415-433-3777 to…

WednesdayMay 17, 2017 9:28 am

NetworkNewsBreaks – CytoDyn Inc. (CYDY) Announces Treatment of First Patient in Phase 2 Trial of PRO 140 for Graft versus Host Disease

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced the treatment of the first patient in its phase 2 clinical trial of PRO 140 for Graft versus Host Disease (GvHD), which represents its leading immunologic indication for the candidate. The multicenter, 60-patient study aims to evaluate the safety and efficacy of PRO 140 in treating GvHD, a potentially life-threatening complication affecting patients requiring a bone marrow transplant due to depleted immune systems. Currently, these transplant patients have just a 40-60% one-year survival rate, and relapsed GvHD is the leading cause of death. “We selected the transplantation indication called GvHD as…

TuesdayMay 16, 2017 12:23 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on May 16, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: EOSS 25.00% – News: Acquires trading base in Taiwan NDEV 17.82% – News: Posts Q1 2017 financial results SPYR 11.86% – News: Develops new Pocket Starships player vs. player feature BHTG 9.47% – News: Posts Q1 2017 financial results LOTE 9.31% – News: Submits proposal on $5M supply and service project GRWG 9.12% – News: Posts Q1 2017 financial results NHLD 6.00% – News: Posts fiscal Q2 2017 financial results NEPT 6.00% – News:…

TuesdayMay 16, 2017 12:20 pm

NetworkNewsBreaks – Great Basin Scientific, Inc. (GBSN) Commences Commercial Launch of Bordetella Direct Test in U.S.; Receives CE Marking in EU

Great Basin Scientific (OTCQB: GBSN) this morning said it is initiating the U.S. commercial launch of its Bordetella Direct Test. The company also said it has received CE Marking designation under the European Directive on In Vitro Diagnostic Medical Devices, marking the company’s sixth assay to receive CE Marking under the directive. The Bordetella Direct Test also increases the company’s commercially available assays in the U.S. to five. “The processes we put in place that resulted in a swift FDA clearance also supported our ability to quickly commercialize the Bordetella Direct Test, much to the relief of many of our…

TuesdayMay 16, 2017 12:18 pm

NetworkNewsBreaks – Mirna Therapeutics, Inc. (NASDAQ: MIRN) Shares Plummet On Merger Agreement with Synlogic

Shares of Mirna Therapeutics (NASDAQ: MIRN) dropped 23% after the company announced its definitive merger agreement with Synlogic, Inc. Per the agreement, Synlogic will merge with a wholly owned subsidiary of Mirna in an all-stock transaction. The merged company will focus on advancing Synlogic’s drug discovery and development platform for Synthetic Biotic medicines and operate under the Synlogic name. Synlogic also recently closed a $42 million Series C preferred stock financing from leading biotechnology investors to finance the merged company. “Following a thorough review of strategic alternatives, we are delighted to announce this transaction with Synlogic, which we believe is…

TuesdayMay 16, 2017 12:14 pm

NetworkNewsBreaks – ChinaNet Online Holdings (NASDAQ: CNET) Trims Net Loss, Increases Revenues in Q1 2017

ChinaNet Online Holdings (NASDAQ: CNET) this morning reported a 43.6% YoY increase in first-quarter revenues, sending shares 12% higher in mid-morning trade. For the three months ended March 31, 2017, total revenues increased to $7.3 million from $5.1 million in the prior year. The increase is primarily due to sales of the company’s search engine marketing, which increased 252.1% to $5.0 million. Alternatively, revenues from Internet advertising and data services were $2.3 million, a decrease of 36.8% from $3.6 million in the first quarter of 2016. Gross profit for the first quarter of 2017 was $1.3 million compared to $1.6…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks